Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities
Conclusion: EGFR-MET signaling is critical for aggressive behaviors of NSCLC and is recognized as a therapeutic target for NSCLC especially for patients with acquired resistance to EGFR-TKI therapy. Our findings demonstrate, for the first time, that LECT2 functions as a suppressor of the progression of NSCLC by targeting EGFR-MET signaling.Cell Physiol Biochem 2018;51:337 –355
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
More News: Biochemistry | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Cytology | Genetics | Hepatocellular Carcinoma | Liver Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Physiology